Our Story

Developing safer, more durable treatments
to improve the lives of patients

AltruBio is developing first-in-class immunomodulators to target diseases of the immune system. Our world-class global team brings a breadth of expertise in immunology and drug development to bring our biologic treatments to patients.  


Our Leadership

AltruBio's senior management is built on a team of individuals possessing strong academic and drug development knowledge, high-level managerial experience and scientific expertise in a range of fields including life science research in immunology, translational sciences, clinical development, technical development, regulatory affairs, financial operation and business development.

Judy Chou, Ph.D.

President and Chief Executive Officer, Chairperson of AltruBio Taiwan Inc.

Jeroen Grasman

Chief Financial Officer

Jesse W. Hall, MD

Chief Medical Officer

Ping-Yang, Yeh, Ph.D.

President of AltruBio Taiwan Inc.

Gene Lee, Ph.D.

Chief Technical Officer

Shih-Yao Lin, MD., Ph.D.

Vice President of Research

Leewen Lin, Ph.D., LL.M.

Vice President of Legal Affairs

Simona Reed, Ph.D.

Vice President of Clinical Operations

Stephen G. Juelsgaard, D.V.M., J.D.

Chairperson of the Board

Sean P. Bohen, M.D., Ph.D.

Judy Chou, Ph.D.

President and Chief Executive Officer, Chairperson of AltruBio Taiwan Inc.

John Doyle

Gur Roshwalb, M.D.

Corsee Sanders, Ph.D.

Patrick Y. Yang, Ph.D.


Joseph B. Kirsner Professor of Medicine at University of Chicago

Bernard Malissen, PhD

Founder and Director of the immunophenomics Center (CIPHE), CIML.

Philip J. Mease, M.D.

Director of the Rheumatology Research Division at Swedish Medical Center/ Providence St. Joseph Health and Clinical Professor of Medicine at the University of Washington in Seattle.

Walter Reinisch, M.D.

Director of the Inflammatory Bowel Disease Study Group, Medical University of Vienna